Veracyte, Inc. — Earnings Quality Grade D
VCYT · Healthcare
Significant concerns
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 32 days, change -7 days YoY
AR growth -4.0% vs revenue growth 16.0%
Revenue 16.0%, CFFO 81.5%. Cash follows revenue
Expense Quality
Inventory -5.5% vs COGS 4.7%. Normal
CapEx growth -14.3% vs revenue 16.0%. Normal
SG&A/Gross Profit = 58.2%. Normal
Gross margin 70.1%, change +3.2pp. Stable
Cash Flow Quality
CFFO/NI = 2.05. Profits backed by cash
FCF $0.1B, FCF/NI = 1.91
Accruals ratio = -5.0%. Low accruals
Cash $0.4B covers debt $0.0B
Balance Sheet Health
Goodwill+Intangibles $0.9B = 65% of equity. Over 50%
Debt/EBITDA = 0.4x. Healthy
Other assets -70.1% vs revenue 16.0%. Normal
Write-offs surged 509% YoY, = 31% of NI. Possible big bath
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change 1% YoY. Normal
Manipulation Score
M-Score = -2.67 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor VCYT continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25